Additional US Listing Information

In September 2022, the Company received shareholder approval to facilitate an additional listing in the US, which is expected to take place in Spring 2023.  Indivior has chosen NASDAQ as its U.S. trading venue. The additional listing is expected to elevate Indivior’s profile in the Company’s largest market and to attract a broader group of biopharma-focused investors and analysts.